Skip to main content
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 2007 Sep 25;104(40):15671–15676. doi: 10.1073/pnas.0707326104

How the regulatory protein, IF1, inhibits F1-ATPase from bovine mitochondria

Jonathan R Gledhill *, Martin G Montgomery *, Andrew G W Leslie †,, John E Walker *,
PMCID: PMC1994141  PMID: 17895376

Abstract

The structure of bovine F1-ATPase inhibited by a monomeric form of the inhibitor protein, IF1, known as I1–60His, lacking most of the dimerization region, has been determined at 2.1-Å resolution. The resolved region of the inhibitor from residues 8–50 consists of an extended structure from residues 8–13, followed by two α-helices from residues 14–18 and residues 21–50 linked by a turn. The binding site in the βDPDP catalytic interface is complex with contributions from five different subunits of F1-ATPase. The longer helix extends from the external surface of F1 via a deep groove made from helices and loops in the C-terminal domains of subunits βDP, αDP, βTP, and αTP to the internal cavity surrounding the central stalk. The linker and shorter helix interact with the γ-subunit in the central stalk, and the N-terminal region extends across the central cavity to interact with the nucleotide binding domain of the αE subunit. To form these complex interactions and penetrate into the core of the enzyme, it is likely that the initial interaction of the inhibitor with F1 forms via the open conformation of the βE subunit. Then, as two ATP molecules are hydrolyzed, the βEE interface converts to the βDPDP interface via the βTPTP interface, trapping the inhibitor progressively in its binding site and a nucleotide in the catalytic site of subunit βDP. The inhibition probably arises by IF1 imposing the structure and properties of the βTPTP interface on the βDPDP interface, thereby preventing it from hydrolyzing the bound ATP.

Keywords: ATP synthase, inhibitor protein, regulation, structure


A variety of ions and natural products inhibit the rotary mechanism of ATP synthase in mitochondria by binding to specific sites in its F1 catalytic domain (1, 2). The antibiotics, the efrapeptins and the aurovertins, inhibit both ATP synthesis and hydrolysis by preventing, respectively, the clockwise and anticlockwise rotation of the central rotor (as viewed from the mitochondrial membrane) (3, 4). They do so by obstructing the closure and opening of catalytic interfaces between the three β-subunits and the three α-subunits. The efrapeptins bind to a site extending from the rotor, across the central cavity of the enzyme, into a catalytic site in a specific β-subunit (the βE-subunit), and two molecules of aurovertin bind simultaneously to equivalent clefts between the nucleotide binding and C-terminal domains of two β-subunits (the βTP- and βE-subunits). Polyphenolic inhibitors, such as resveratrol, quercetin, and piceatannol, bind to a common site between the tip of the rotary central stalk and the βTP-subunit in the annular sleeve of the “bearing” formed by loop regions below the “crown” of β-strands in the N-terminal domains of the α- and β-subunits, and prevent the rotor from turning in either direction (5).

Azide enhances the binding of an ADP molecule to one of the three catalytic sites in the β-subunits (6) and is a potent inhibitor of ATP hydrolysis by ATP synthase, but it does not inhibit ATP synthesis (7). Similarly, IF1, the natural inhibitor protein found in mitochondria, prevents the hydrolysis, but not the synthesis of ATP by the ATP synthase (8). The protein fold of the 84-aa chain of bovine IF1 is dominated by an α-helix 90 Å in length, and the active inhibitor is a homodimer where residues 49–81 form an antiparallel α-helical coiled-coil, leaving each inhibitory N-terminal region accessible for interaction with an F1 catalytic domain (9). This dimeric state is favored by pH values <7.0, and at higher values the dimers associate to form higher oligomers, thereby occluding the inhibitory region and masking its inhibitory activity (9, 10). During cellular ischaemia, glycolysis becomes the only source of ATP, and so the pH of the cytosol and the mitochondrial matrix decrease (8, 11). It is thought that this acidification of the mitochondrial matrix promotes the formation of the active dimeric state of IF1, the binding of the dimeric IF1 to the F1 domains of two ATP synthase complexes, and the inhibition of ATP hydrolysis (12).

In the structure of the dimeric IF1 associated with two F1-ATPase moieties [known as (F1-IF1)2], the N-terminal inhibitory region of IF1 is bound to a catalytic interface between the C-terminal regions of the αDP- and βDP-subunits, but because of disorder in the crystals, the precise details of the interaction between the inhibitor and the enzyme could not be described (12). The coiled-coil region is not required for inhibitory activity, and residues 14–47 have been defined by deletion analysis as the minimal inhibitory sequence (13). Therefore, as presented in this article, bovine F1-ATPase has been inhibited by an active monomeric N-terminal fragment of bovine IF1 consisting of residues 1–60 plus a C-terminal histidine6 sequence, known as I1–60His. The complex between I1–60His and F1-ATPase has been crystallized and solved by x-ray crystallography at 2.1-Å resolution, thereby revealing the precise mode of binding of the inhibitor to F1-ATPase in the inhibited complex.

Results and Discussion

Characterization of Inhibitor Proteins.

The molecular masses measured by mass spectrometry of bovine IF1, and of the monomeric forms I1–60 and I1–60His, agreed with the values calculated from their sequences [see supporting information (SI) Table 2]. The inhibitory potency of I1–60 determined with F1-ATPase at pH 6.7 was very similar to that of the native inhibitor IF1 (see SI Fig. 5), and it was retained at higher pH values, whereas the potency of the native inhibitor declined with increasing pH. As expected, the complex between F1-ATPase and I1–60His had a similar apparent molecular mass (370 kDa) to F1-ATPase, whereas the complex between F1-ATPase and the native inhibitor was estimated to be 700 kDa (SI Fig. 6). These values are consistent with the former complex being monomeric, consisting of one molecule of I1–60His associated with one F1-ATPase complex, and the latter being a dimeric complex with two F1 complexes bound to the dimeric inhibitor, as described (12).

Structure of the F1-I1–60His Complex.

The diffraction properties of crystals of the F1-I1–60His complex were improved by shrinking the unit cell, especially in the a dimension, by changing the relative humidity from 98.5% to 98.0–97.5% by controlled dehydration. Similar benefits derived from controlled dehydration of crystals of bovine F1-ATPase grown in the presence and absence of azide have been described (6, 14). Quaternary structural changes relative to the reference (14, 15) and (F1-IF1)2 structures can be attributed to increased lattice contacts (see SI Text).

The structure of the complex (Fig. 1) was solved by molecular replacement (see Materials and Methods) using data to 2.1 Å. Data processing and refinement statistics are summarized in Table 1. The final model of the F1-I1–60His complex contains the following residues: αE, 24–510; αTP, 24–401 and 410–510; αDP, 23–404, 410–483, and 494–510; βE, 10–474; βTP, 9–474; βDP, 9–477; γ, 1–59, 65–96, and 101–272; δ, 15–145; ε, 1–47; and IF1, 8–50. The nucleotide binding sites in each of the three noncatalytic α-subunits contained mainly Mg-ATP. In the αE- and αDP-subunits there was evidence from the refined temperature factors for the presence of some Mg-ADP, and the occupancy of the γ-phosphate moiety in these subunits was estimated to be 75%. The βDP- and βTP-subunits both contained Mg-ADP, and the βE-subunit had no bound nucleotide, but, as in many previous structures (1620), there was electron density in the vicinity of the P-loop residues 157–163 that was interpreted as bound phosphate (or sulfate).

Fig. 1.

Fig. 1.

The structure of the bovine F1-I1–60His complex. (A) Overall view of the complex. The α-, β-, γ-, δ-, and ε-subunits are shown in ribbon form in red, yellow, dark blue, magenta, and green, respectively. Residues 8–50 of I1–60His are shown in light blue solid representation. (B) View upward (away from the foot of the central stalk), along the axis of the γ-subunit showing the orientation of the long α-helix of I1–60His relative to the C-terminal domains of the α- and β-subunits. The N- and C-terminal ends of the I1–60His are labeled N and C, respectively.

Table 1.

Data processing and refinement statistics for the complex between bovine F1-ATPase and I1–60His

Space group P212121
Unit cell dimensions a, b, c, Å 262.5, 103.3, 135.6
Resolution range, Å 69.7–2.1
No. of unique reflections 212,416 (30,284)
Multiplicity 3.5 (3.1)
Completeness, % 99.2 (97.7)
Rmerge,* 10.6 (42.1)
<I/σ(I)> 9.1 (2.0)
B factor, from Wilson, Å2 31.0
Water molecules 1,923
R factor, % 19.0
Free R factor, % 24.5
rmsd of bonds, Å 0.01
rmsd of angles, ° 1.2

Statistics for the highest resolution bin (2.21–2.10 Å) are shown in parentheses.

*Rmerge = ΣhΣi|I(h) − I(h)ihΣiI(h), where I(h) is the mean weighted intensity after rejection of outliers.

R = ΣhklFobs|−k|Fcalc‖ /Σhkl |Fobs|, where Fobs and Fcalc are the observed and calculated structure factor amplitudes.

Rfree = Σhkl⊂TFobs|−k|Fcalc‖ /ΣhklT |Fobs|, where Fobs and Fcalc are the observed and calculated structure factor amplitudes and T is the test set of data omitted from refinement (5% in this case).

In this structure, the resolved region of I1–60His from residues 8–50 consists of an extended structure from residues 8–13, followed by two α-helices from residues 14–18 and residues 21–50, linked by a turn from residues 19–20. Residues 1–7 and 51–60 plus the His tag were not resolved. In the structure of the dimeric IF1, in which residues 19–83 were resolved (9), the α-helical region from residues 22–50 continues unbroken beyond residue 50 up to residue 81, and the two monomers are dimerized by residues 49–81, which form an antiparallel α-helical coiled-coil.

The longer helix (residues 21–50) of I1–60His extends for 42 Å. Residues 47–50 lie outside of the F1 domain and are not in contact with it, whereas the rest of the structure of I1–60His lies within it. Its binding site in F1-ATPase is complex and involves five subunits of F1-ATPase. The most significant contributors are the βDP-, αDP- and γ-subunits, and the βTP- and αE-subunits provide additional minor contributions. All of the residues in the βDP-, αDP-, and βTP-subunits that are involved in forming the binding site lie within their C-terminal domains, whereas the regions involved in the αE-subunit are in the nucleotide binding domain. The long helix of I1–60His extends in a C- to N-terminal direction from the external surface of the F1 domain to the central cavity surrounding the γ-subunit. Its path rises steeply from the outside at an angle of ≈45° to the central axis of the γ-subunit. Near to the external surface of the F1 domain, the binding site consists of a deep groove beneath the C-terminal domain of the βDP subunit. The entrance to the binding groove is somewhat constricted by the ε-subunit in the vicinity of residue 47 in its C-terminal region. Lys-48 is widely conserved (although not in fungi), but residues 48–50 at the C terminus of the ε-subunit were not resolved (as in previous structures), and there is no evidence of any direct contact between I1–60 and the C-terminal region of the ε-subunit. The binding groove itself is formed from the C-terminal helix (or helix 6) and helix 2 of the βDP-subunit, which interact at right angles near to their N- and C-terminal ends, respectively, and the loop (residues 447–453) linking helices 4 and 5 (Fig. 2A). Then the binding site continues inward via a cleft between the βDP- and αDP-subunits. This cleft is formed from the C-terminal end of helix 1 in the βDP-subunit and the loop linking it to helix 2, and the C-terminal ends of helices 1 and 2 in the αDP-subunit (Fig. 2B). From the cleft, the N-terminal end of the long helix emerges into the central cavity of the α3β3γ-subcomplex, making contacts with the C-terminal ends of helix 1 in both the βDP- and βTP-subunits, and with the N-terminal helix of the γ-subunit (Fig. 2 C and D). At this point, the chain turns abruptly right (as viewed from the side of the F1 particle), at almost 90°, allowing the linker (residues 19–20) between the short and long helices, and the short helix itself (residues 14–18), to make more contacts with the N-terminal helix of the γ-subunit. The unstructured region (residues 8–13) preceding the short helix snakes around the N-terminal α-helix of the γ-subunit in an anticlockwise direction (as viewed from the mitochondrial membrane), emerges into the central cavity, and crosses it, making contacts with the nucleotide binding domain of the αE-subunit (Fig. 2D). This description of the fold of IF1 is similar to that described before in the (F1-IF1)2 complex, but in the earlier complex, because of the difficulties of interpretation associated with statistical disorder in the crystals, the register of the sequence of IF1 was incorrect (12); in the current structure, the sequence is shifted by 8 aa toward the N terminus relative to the earlier structure. In a comparison of the βDP-subunit of the F1-I1–60His complex with the same subunit of the ground-state structure, the only significant change in conformation is in the region of residues 382–398 at the C-terminal end of helix 1 and the loop joining helices 1 and 2. This region provides many of the interactions with the inhibitor protein and shows displacements of up to 2.9 Å, and the equivalent region of the αDP-subunit, helices 1 and 2, and the joining loop (residues 389–417) is displaced by up to 5 Å.

Fig. 2.

Fig. 2.

The binding site for I1–60His in bovine F1-ATPase. (A and B) Ribbon and solid representations, respectively, of the binding site groove formed from α-helices and loops between them in the C-terminal domains of the βDP-, αDP-, and βTP- subunits, occupied by the long helix (residues 21–50) of I1–60His (light blue). The N- and C-terminal ends of the I1–60HIS are labeled N and C, respectively, in A. (B) The orange side chains are those of the strictly conserved residues Lys-24, Arg-25, and Glu-26 of I1–60His that do not interact with F1-ATPase. (C and D) Interactions between residues 8–46 and F1-ATPase. (C) View from the side of the central stalk showing the orientation of I1–60His relative to the γ-subunit. The N- and C-terminal ends of the I1–60HIS are labeled N and C, respectively. (D) View down along the axis of the γ-subunit showing the interaction of the short helix with the γ-subunit and the interaction between the extended region formed by residues 10–12 of I1–60His and side chains in the nucleotide binding domain of the αE-subunit.

The detailed interactions between I1–60His and F1-ATPase are both extensive and complicated. Among the most significant are hydrophobic interactions between the βDP-subunit and residues Tyr-33 and Phe-34 in the inhibitor protein (see Fig. 3A), and a network of polar and ionic interactions involving residues Glu-29, Glu-30, Arg-32, and Arg-35 of the inhibitor protein with residues mainly in the βDP-subunit, but also in the αDP-subunit (Fig. 3B). There are salt bridges between Glu-29 and Arg-32, and between Glu-31 and Arg-35, which may help to orient the inhibitor protein, but the residues are not strictly conserved. Nine residues in the long α-helix are absolutely conserved (Fig. 3 and SI Fig. 7). Four of them, Phe-22, Ala-28, Leu-42, and Leu-45, sit in hydrophobic pockets and contribute to the binding of I1–60 to F1-ATPase. In contrast, four polar residues, Lys-24, Arg-25, Glu-26, and Glu-40, make no direct contacts whatever with the F1-ATPase, and their side chains are exposed in the aqueous phase. Their roles are somewhat obscure, but they could be helping to orient the long α-helix with respect to its binding pocket, or they may have roles in the earlier stages of binding the inhibitor protein to F1-ATPase during a rotary catalytic cycle (see Formation of the Inhibited Complex). Only one totally conserved polar residue, Glu-30, appears to be contributing significantly to the binding of the inhibitor via a series of polar interactions, already described above. One additional absolutely conserved residue, Gly-13, is in the extended region immediately preceding the short α-helix (residues 14–17). The possible significance of the region from residues 8–21, which are not part of the minimal inhibitory sequence, will be discussed in the next section.

Fig. 3.

Fig. 3.

The structure of bovine I1–60His and its interactions with bovine F1-ATPase. The resolved region from residues 8–50 is shown in light blue. (A) All of the residues that interact with F1-ATPase are shown. The purple residues are those that are strictly conserved and interact with F1-ATPase. (B) Polar interacting side chains of I1–60His and the βDP-subunit (yellow) and αDP-subunit (red). The purple residue (E30) is strictly conserved in all known sequences of IF1. (C) Conserved interacting side chains are purple, and those that are strictly conserved but do not interact with F1-ATPase are orange.

Formation of the Inhibited Complex.

The extensive binding site of I1–60His in F1-ATPase has a buried surface area of 2,200 Å2, and the region of interaction with the C-terminal domain of the βDP-subunit is the major contributor (1,100 Å2). In the ground-state structure of F1-ATPase, the conformations of the C-terminal domains of all three β-subunits are very similar. The main difference is in the region of residues 384–399, which interact with the γ-subunit differently from one β-subunit to another. This region also interacts with the inhibitor protein in the structure of F1-I1–60His. Therefore, the binding site for the inhibitor protein is largely present in all three β-subunits, and modeling shows that the conformational changes observed on inhibitor binding to the βDP-subunit can be accommodated in the βE-subunit without introducing any steric clashes with the γ-subunit. However, the IF1 binding sites in the βDPDP and the βTPTP interfaces of the reference structure are buried almost entirely, and it is unlikely that these interfaces will be perturbed by large-scale structural fluctuations. Therefore, the structural evidence does not support the proposal that, during inhibition of ATP hydrolysis by IF1, the inhibitor must bind first at the βTPTP interface of F1-ATPase (21, 22). The only binding site accessible to the long helix of I1–60His is that which lies in the βEE interface (helices 1, 2, and 6 in subunit βE; helices 1 and 2 in subunit αE), and it is more likely that the initial binding of IF1 takes place at the βEE interface, as proposed (12). At this early stage of binding, few or no interactions will be likely to have formed between IF1 and the αE-subunit, and the interactions between IF1 and the βE-subunit will be limited to residues 21–46 of the inhibitor. It is not known whether the N-terminal region of IF1 (residues 1–20) will have formed interactions with F1-ATPase, and it may be disordered, as in the structure of dimeric IF1. The low affinity of IF1 in the absence of ATP (21, 22) and the limited nature of the interactions between F1-ATPase and IF1 at this stage of binding are consistent with this proposal. Partial closure of the βE-subunit after ATP binding may increase the affinity of the inhibitor protein.

At the next stage, ATP hydrolysis and rotation of the γ-subunit by 120° will convert the βEE interface to the βTPTP interface. During this transition, it is likely that the unstructured N-terminal region of IF1 will wrap around the γ-subunit and become structured, as observed in the F1-I1–60His structure. However, to accommodate IF1, the βTPTP interface must remain partially open so as to resemble the βDPDP interface in the F1-I1–60His structure, and a second potential IF1 binding site will become exposed in the newly formed βE-subunit. However, it is likely that a second IF1 will be prevented from binding tightly as modeling suggests that the position of the γ-subunit will block the binding site for the N-terminal region of IF1. In the next step of the inhibition process, a second ATP molecule is hydrolyzed, resulting in a second 120° rotation of the γ-subunit, and the βTPTP interface will be converted to the βDPDP interface, with IF1 bound at the latter site. This scheme assumes that IF1 bound at the βTPTP interface, resulting in the incomplete closure of this catalytic interface (as confirmed by modeling), does not prevent the second hydrolysis step, and that the normal catalytic sequence is followed up to the state observed in the crystal structure. As the kinetic pathway from initial binding to the final inhibited state has not been characterized, other pathways (involving, for example, a rotation of the γ-subunit without hydrolysis of ATP) remain possible.

This proposal does not specify on which of three β-subunits ATP hydrolysis occurs. Two possible schemes of ATP hydrolysis by F1-ATPase have been described (17), and the related schemes of inhibition of ATP hydrolysis by the inhibitor protein are shown in Fig. 4. In Fig. 4A, which is supported by single-molecule experiments (23), ATP hydrolysis occurs at the catalytic interface where the inhibitor is bound to progress from state II to state III. However, the structure suggests that this transition is unfavorable as the catalytic residue αArg-373 is not correctly positioned, and therefore it is likely to be slow. Fig. 4B has no such requirement, and therefore it might be considered to be preferable. The two schemes differ by ADP being bound to the βDP-subunit in A and ATP in B. However, ATP hydrolysis is likely to occur in the βDP-subunit on the time scale of the crystallization process, even with the inhibitor protein bound, as has been observed in F1-ATPase inhibited with efrapeptin (3). Therefore, the structure of F1-I1–60His does not help to determine which scheme is preferrable.

Fig. 4.

Fig. 4.

Possible schemes of the inhibition of F1-ATPase by the inhibitor protein. F1-ATPase is depicted as viewed from the foot of the central stalk. For simplicity, only the catalytic β-subunits and the γ-subunit are shown. (A) In state I, the inhibitor protein and ATP bind to the βE-subunit. ATP binding promotes the anticlockwise rotation of the γ-subunit, leading to hydrolysis of ATP bound to the βTP-subunit as it converts into the βDP-subunit. Both ATP binding to the βE-subunit and ATP hydrolysis on the βTP-subunit that is converting to the βDP-subunit are required for a 120o rotation of the γ-subunit. In state II, ADP and phosphate are released, and ATP binds to the newly formed βE-subunit. ATP binding drives the anticlockwise rotation of the γ-subunit, and this rotation is linked to hydrolysis of ATP on the βTP-subunit as it converts to the βDP-subunit. The second 120o rotation of the γ-subunit is generated to give state III, the fully inhibited form. (B) ATP hydrolysis takes place on the βDP-subunit after binding of ATP to the βE-subunit. As in A, two rounds of ATP binding and hydrolysis are required to give the fully inhibited form shown in state III. The crystal structure of F1-I1–60His represents state III in this scheme, and the reference (or ground state) structure corresponds to state I.

Mechanism of Inhibition by IF1.

In the F1-I1–60His complex, as in (F1-IF1)2, the overall conformation of the βDPDP catalytic interface resembles the βTPTP catalytic interface in the reference structure (14, 15). Several pieces of evidence indicate that in the active enzyme, ATP hydrolysis takes place at the βDP catalytic site and not the βTP catalytic site (6, 17). For example, in the ground-state analog structure, BeF3.F1 (17), the guanidinium of the catalytically essential “arginine finger” residue αArg-373 (15), and consequently the attacking nucleophilic water molecule, are significantly further away from the analog of the γ-phosphate of ATP in the βTP-subunit than in the βDP- subunit, hence disfavoring ATP hydrolysis in the βTP-subunit. In the various structures of F1-ATPase, the side chain of αArg-373 adopts either an “inward pointing” position or an “outward pointing” position. In both the βDP and βTP catalytic sites of the reference structure, of the ADP-azide inhibited enzyme (6, 14, 15), and of ground-state and transition-state analog structures formed with metallo-fluorides (1719), αArg-373 points in toward the catalytic site with its guanidinium group interacting with the β- and γ-phosphates (or their γ-phosphate analogs, BeF3 or AlF4, or with azide). This position is consistent with its proposed role in stabilizing the pentavalent intermediate in ATP hydrolysis (15). In contrast, in the βTPTP catalytic interface in the structures of F1-ATPase inhibited by dicyclohexyl-carbodiimide (20), where ADP is bound in the βTP catalytic site, and in a form of the enzyme with ADP bound to both βTP and βDP catalytic sites (17), the side chain of αTPArg-373 is oriented away from the phosphates of the bound ADP molecules. Hence, the inward and outward pointing positions correlate with the presence of a nucleotide with or without a γ-phosphate moiety, respectively. In the F1-I1–60His structure, αDPArg-373 points outward, with its guanidinium group stacked against that of βDPArg-191. Hence, the outward pointing conformation of this residue correlates with ADP being bound to the βDP catalytic site. When ATP is present, as indicated by the (F1-IF1)2 structure, where AMPPNP was bound to the βDP-subunit, αDPArg-373 will adopt the more usual inward pointing conformation. Modeling αDPArg-373 in the inward pointing conformation in the F1-I1–60His structure places the guanidinium group ≈1 Å further away from the active site than in the reference structure, disfavoring ATP hydrolysis at this site. A structure of F1-ATPase inhibited by I1–60His with a nonhydrolysable analog of ATP bound to the βDP catalytic site would help to clarify this point further.

Two possible explanations for mechanism of inhibition of F1-ATPase by IF1, corresponding to schemes A and B (Fig. 4) suggest themselves. In scheme A, hydrolysis of ATP bound to the βDP-subunit is required to reach state III, despite the inhibitor protein being bound at that catalytic interface.

Then the final state III represents a fully inhibited form because the extensive interactions between the inhibitor protein and the αDP- and βDP-subunits stabilize the αDPDP interface, so that ATP binding to the βE-subunit is no longer able to generate the rotation of the γ-subunit, as partial opening of the interface is required for rotation. Alternatively, in scheme B, the inhibitor protein prevents the hydrolysis of ATP bound to the βDP-subunit required for the next 120° rotation of the γ-subunit. Thus, the inhibition arises from the disruption of the catalytic site. Further experiments are required to distinguish between these two possibilities. While the inhibited state with bound ATP has similarities to a “prehydrolysis state” (12), it resembles most closely a “dead-end” product (24, 25). The reversal of rotation of the central stalk in the ATP synthase leads to the reactivation of the enzyme and the expulsion of the inhibitor protein by the conversion of the βDPDP interface to the βEE interface.

Materials and Methods

Crystallization of the F1-I1–60His Complex.

The conditions for growth of crystals were based on those used for crystallizing the dimeric F1-IF1 complex (12). An ammonium sulfate precipitate of F1-ATPase was dissolved in a minimum volume of buffer prepared in D2O containing 100 mM Tris·HC1 (pH 8.2), 40 mM MgCl2, 2 mM EDTA, and 0.004% (wt/vol) PMSF. This solution was passed through a Micro Bio-Spin P-6 column (BioRad Laboratories, Hemel Hempstead, U.K.), and the protein concentration of the eluate was adjusted to 10 mg·ml−1. This solution was mixed with a 4-fold molar excess of purified Il-60His in the same buffer, and the solution was kept at 23°C for 60–90 min. Then 1 mM ATP was added from a 100-mM neutralized stock solution. After an additional 15–20 min, the inhibition of F1-ATPase was complete, and NaCl (300 mM) and spermidine (5 mM) were added from neutralized stock solutions. This solution was centrifuged (4,000 × g, 5 min, 23°C), and then dispensed into 72-well microbatch plates (Nalge Europe, Hereford, U.K.) coated with decane. The drops were made of the protein solution (3 μl; 10 mg·ml−1) to which was added 3 μl of either PEG 4000 from 21.25% to 24% (wt/vol) or PEG 6000 from 18% to 20.75% (wt/vol). Both polyethylene glycols were dissolved in D2O. The plates were covered with filtered liquid paraffin (5 ml; BDH Laboratory Supplies, Poole, U.K.) and kept at 23°C. Small crystals had formed within a few hours, and their growth was complete in 2 weeks. Analysis of the crystals by SDS/PAGE showed that the subunits of F1-ATPase and I1–60His had remained intact during crystal growth, and there was no indication of proteolytic degradation.

A harvest solution, identical to the buffer in the crystallization drops, but containing an additional 2% (wt/vol) of the polyethylene glycol, was added to the drops, and the crystals of the F1-Il-60His complex were harvested with micromesh cryoloops (MiTeGen, Ithaca, NY). They were introduced into a free-mounting system (Proteros Biostructures, Martinsried, Germany) where any excess mother liquor was wicked away. The crystals were dehydrated gradually by controlled reduction of the relative humidity, and their x-ray diffraction properties were monitored. Reduction of the relative humidity from the initial value of 98.5% to 98–97.5% improved both the resolution limit and mosaic spread of the diffraction data significantly. Then the crystals were covered in perfluoropolyether (PFO X125/03; Alfa Aesar, Lancashire, U.K.), plunged into liquid nitrogen and stored at 100 K.

Data Collection.

Diffraction data were collected to 2.1-Å resolution on a Q210 charge-coupled detector from Area Detector Systems (Poway, CA) on beam line ID29 (λ = 0.979 Å) at the European Synchrotron Radiation Facility, Grenoble, France. They were processed with MOSFLM (26) and other programs from The Collaborative Computational Project 4 suite (27).

Solution and Refinement of the Structure.

The structure of F1-ATPase inhibited with I1–60His was solved by molecular replacement with AMoRe (28). The starting model was one (complex A) of the two F1 complexes from the dimeric F1-IF1 structure (Protein Data Bank ID code 1OHH) without IF1. No water molecules had been modeled into this dimeric structure. Refinement was carried out with REFMAC (29), alternating with manual rebuilding with COOT (30). TLS parameters were refined in the final stages. Some water molecules were built with ARP/warp (31). The stereochemistry of the model was assessed with PROCHECK (32), and figures were produced with PyMol (33).

See SI Text for cloning and overexpression of I1–60His, purification and characterization of proteins, assay of inhibition of F1-ATPase, and estimation of molecular weights of complexes.

Supplementary Material

Supporting Information

Acknowledgments

We thank Dr. I. M. Fearnley for mass spectrometric measurements and the beamline staff at the European Synchrotron Radiation Facility for assistance with data collection. This work was supported by the Medical Research Council. J.R.G. was supported partly by a Research Studentship from Trinity College, Cambridge, U.K.

Footnotes

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

Data deposition: Coordinates and structure factors of the F1-I1–60HIS complex have been deposited in the Protein Data Bank, www.pdb.org (PDB ID code 2v7q).

This article contains supporting information online at www.pnas.org/cgi/content/full/0707326104/DC1.

References

  • 1.Walker JE, Gledhill JR. In: Biophysical and Structural Aspects of Bioenergetics. Wikstrom M, editor. Cambridge, UK: R Soc Chem; 2005. pp. 334–358. [Google Scholar]
  • 2.Gledhill JR, Walker JE. Biochem Soc Trans. 2006;34:989–992. doi: 10.1042/BST0340989. [DOI] [PubMed] [Google Scholar]
  • 3.Abrahams JP, Buchanan SK, van Raaij MJ, Fearnley IM, Leslie AGW, Walker JE. Proc Natl Acad Sci USA. 1996;93:9420–9424. doi: 10.1073/pnas.93.18.9420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.van Raaij MJ, Abrahams JP, Leslie AGW, Walker JE. Proc Natl Acad Sci USA. 1996;93:6913–6917. doi: 10.1073/pnas.93.14.6913. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Gledhill JR, Montgomery MG, Leslie AGW, Walker JE. Proc Natl Acad Sci USA. 2007;104:13632–13637. doi: 10.1073/pnas.0706290104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Bowler MW, Montgomery MG, Leslie AGW, Walker JE. Proc Natl Acad Sci USA. 2006;103:8646–8649. doi: 10.1073/pnas.0602915103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Zharova TV, Vinogradov AD. J Biol Chem. 2004;279:12319–12324. doi: 10.1074/jbc.M311397200. [DOI] [PubMed] [Google Scholar]
  • 8.Walker JE. Curr Opin Struct Biol. 1994;4:912–918. doi: 10.1016/0959-440x(94)90274-7. [DOI] [PubMed] [Google Scholar]
  • 9.Cabezon E, Runswick MJ, Leslie AGW, Walker JE. EMBO J. 2001;20:6990–6996. doi: 10.1093/emboj/20.24.6990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Cabezon E, Butler PJ, Runswick MJ, Walker JE. J Biol Chem. 2000;275:25460–25464. doi: 10.1074/jbc.M003859200. [DOI] [PubMed] [Google Scholar]
  • 11.Green DE, Grover GJ. Arch Biochim Biophys. 2000;1458:343–355. doi: 10.1016/s0005-2728(00)00085-2. [DOI] [PubMed] [Google Scholar]
  • 12.Cabezon E, Montgomery MG, Leslie AGW, Walker JE. Nat Struct Biol. 2003;10:744–750. doi: 10.1038/nsb966. [DOI] [PubMed] [Google Scholar]
  • 13.van Raaij MJ, Orriss GL, Montgomery MG, Runswick MJ, Fearnley IM, Skehel JM, Walker JE. Biochemistry. 1996;35:15618–15625. doi: 10.1021/bi960628f. [DOI] [PubMed] [Google Scholar]
  • 14.Bowler MW, Montgomery MG, Leslie AGW, Walker JE. J Biol Chem. 2007;282:14238–14242. doi: 10.1074/jbc.M700203200. [DOI] [PubMed] [Google Scholar]
  • 15.Abrahams JP, Leslie AGW, Lutter R, Walker JE. Nature. 1994;370:621–628. doi: 10.1038/370621a0. [DOI] [PubMed] [Google Scholar]
  • 16.Orriss GL, Leslie AGW, Braig K, Walker JE. Structure (London) 1998;6:831–837. doi: 10.1016/s0969-2126(98)00085-9. [DOI] [PubMed] [Google Scholar]
  • 17.Kagawa R, Montgomery MG, Braig K, Leslie AGW, Walker JE. EMBO J. 2004;23:2734–2744. doi: 10.1038/sj.emboj.7600293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Braig K, Menz RI, Montgomery MG, Leslie AGW, Walker JE. Structure (London) 2000;8:567–573. doi: 10.1016/s0969-2126(00)00145-3. [DOI] [PubMed] [Google Scholar]
  • 19.Menz RI, Walker JE, Leslie AGW. Cell. 2001;106:331–341. doi: 10.1016/s0092-8674(01)00452-4. [DOI] [PubMed] [Google Scholar]
  • 20.Gibbons C, Montgomery MG, Leslie AGW, Walker JE. Nat Struct Biol. 2000;7:1055–1061. doi: 10.1038/80981. [DOI] [PubMed] [Google Scholar]
  • 21.Corvest V, Sigalat C, Venard R, Falson P, Mueller DM, Haraux F. J Biol Chem. 2005;280:9927–9936. doi: 10.1074/jbc.M414098200. [DOI] [PubMed] [Google Scholar]
  • 22.Corvest V, Sigalat C, Haraux F. Biochemistry. 2007;46:8660–8688. doi: 10.1021/bi700522v. [DOI] [PubMed] [Google Scholar]
  • 23.Nishizaka T, Oiwa K, Noji H, Kimura S, Muneyuki E, Yoshida M, Kinosita K., Jr Nat Struct Mol Biol. 2004;11:142–148. doi: 10.1038/nsmb721. [DOI] [PubMed] [Google Scholar]
  • 24.Penin F, Di Pietro A, Godinot C, Gautheron DC. Biochemistry. 1988;27:8969–8974. doi: 10.1021/bi00425a014. [DOI] [PubMed] [Google Scholar]
  • 25.Pedersen PL, Schwerzmann K, Cintron NM. Curr Top Bioenerg. 1981;11:149–199. [Google Scholar]
  • 26.Leslie AGW. Joint CCP4 and EACMB Newsletter on Protein Crystallography. Warrington, UK: Daresbury Laboratory; 1992. [Google Scholar]
  • 27.Collaborative Computational Project 4. Acta Crystallogr D. 1994;50:760–763. [Google Scholar]
  • 28.Navaza J. Acta Crystallogr A. 1994;50:157–163. [Google Scholar]
  • 29.Murshudov GN, Vagin AA, Dodson EJ. Acta Crystallogr D. 1997;53:157–163. doi: 10.1107/S0907444996012255. [DOI] [PubMed] [Google Scholar]
  • 30.Emsley P, Cowtan K. Acta Crystallogr D. 2004;60:2126–2132. doi: 10.1107/S0907444904019158. [DOI] [PubMed] [Google Scholar]
  • 31.Lamzin VS, Wilson KS. Acta Crystallogr D. 1993;49:129–147. doi: 10.1107/S0907444992008886. [DOI] [PubMed] [Google Scholar]
  • 32.Laskowski RA. J Appl Crystallogr. 1993;26:283–291. [Google Scholar]
  • 33.DeLano WL. The Pymol Molecular Graphics System. San Carlos, CA: DeLano Scientific; 2002. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting Information
pnas_0707326104_1.pdf (234.1KB, pdf)
pnas_0707326104_2.pdf (1.5MB, pdf)
pnas_0707326104_3.pdf (231.2KB, pdf)

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES